Hyponatraemia during oxcarbazepine therapy.

Article Details

Citation

Pendlebury SC, Moses DK, Eadie MJ

Hyponatraemia during oxcarbazepine therapy.

Hum Toxicol. 1989 Sep;8(5):337-44.

PubMed ID
2680897 [ View in PubMed
]
Abstract

A clinical and pharmacokinetic study was carried out progressively substituting a new anticonvulsant oxcarbazepine for its congener carbamazepine in a group of patients with refractory epilepsy. Although oxcarbazepine showed possible though not statistically significant advantages of better seizure control and was probably less sedating, its use was associated with a dose-dependent reduction in plasma sodium levels in 12 of 15 patients. The mean plasma sodium level fell from 137.5 +/- 5.2 (s.d.) to 128.5 +/- 6.1 mE/l. Imposed restriction of fluid intake may have minimized the degree of hyponatraemia. This adverse effect may limit the role of the drug as an anticonvulsant or necessitate special precautions when it is used. However, the possibility of employing the drug in diabetes insipidus may be worth exploring.

DrugBank Data that Cites this Article

Pharmaco-metabolomics
DrugDrug GroupsMetaboliteChangeDescription
OxcarbazepineApprovedSodium
decreased
Oxcarbazepine decreases the level of Sodium in the blood